NASDAQ:IPHA Innate Pharma (IPHA) Stock Price, News & Analysis $0.87 -0.07 (-7.76%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Innate Pharma Stock (NASDAQ:IPHA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innate Pharma alerts:Sign Up Key Stats Today's Range$0.83▼$0.9250-Day Range$0.94▼$2.0152-Week Range$0.83▼$2.71Volume16,930 shsAverage Volume76,498 shsMarket Capitalization$96.86 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingModerate Buy Company Overview Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners. Innate Pharma conducts research and clinical development in France and works with international partners, including companies such as AstraZeneca and Sanofi. Its activities are centered on advancing investigational therapies rather than marketing a broad portfolio of approved medicines.AI Generated. May Contain Errors. Read More Innate Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIPHA MarketRank™: 2.49965729952 of 5 starsInnate Pharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 486th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingInnate Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInnate Pharma has a consensus price target of $5.67, representing about 573.0% upside from its current price of $0.84.Amount of Analyst CoverageInnate Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Innate Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Innate Pharma are expected to grow in the coming year, from ($0.53) to ($0.45) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.16% of the float of Innate Pharma has been sold short.Short Interest Ratio / Days to CoverInnate Pharma has a short interest ratio ("days to cover") of 8.92.Change versus previous monthShort interest in Innate Pharma has recently decreased by 2.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.50 News SentimentInnate Pharma has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Innate Pharma this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.16% of the stock of Innate Pharma is held by institutions.Read more about Innate Pharma's insider trading history. Receive IPHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPHA Stock News HeadlinesInnate Pharma S.A. (IPHA) Discusses IPH4502 Phase 1 Clinical Data and Development Outlook TranscriptNovember 19 at 1:31 AM | seekingalpha.comInnate Pharma stock tumbles after phase 1 trial dataNovember 18 at 3:28 PM | finance.yahoo.comAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution.November 20 at 1:00 AM | Brownstone Research (Ad)Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026November 18 at 2:30 AM | businesswire.comInnate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026November 11, 2026 | businesswire.comInnate Pharma S.A. (IPHA) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comInnate Pharma Reports Third Quarter 2026 Business and Financial UpdateNovember 5, 2026 | finance.yahoo.comInnate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027October 27, 2026 | finance.yahoo.comSee More Headlines IPHA Stock Analysis - Frequently Asked Questions How have IPHA shares performed this year? Innate Pharma's stock was trading at $1.75 at the beginning of 2026. Since then, IPHA shares have decreased by 51.9% and is now trading at $0.8420. When did Innate Pharma IPO? Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Innate Pharma? Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Tesla (TSLA), Viking Therapeutics (VKTX), Block (XYZ), Voyager Therapeutics (VYGR), NIO (NIO), Pfizer (PFE) and Advanced Micro Devices (AMD). Company Calendar Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, IPHA's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IPHA CIK1598599 Webwww.innate-pharma.com Phone33-4-30-30-30-30FaxN/AEmployees163Year Founded1999Price Target and Rating Average Price Target for Innate Pharma$5.67 High Price Target$9.00 Low Price Target$1.00 Potential Upside/Downside+553.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick RatioN/A Sales & Book Value Annual Sales$10.19 million Price / Sales9.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-3.33Miscellaneous Outstanding Shares111,720,000Free Float76,092,000Market Cap$96.86 million OptionableNot Optionable Beta0.78 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:IPHA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our Partners$85.7 billion from the SpaceX IPO, and where it may go nextA stock trading under $1 could announce a supply deal with Elon Musk. Similar partnership announcements have s...Brownstone Research | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.